9-Methyl-β-Carboline for Health & Longevity - Quick Reference Sheet

9-Methyl-β-Carboline for Health & Longevity

Created on 07/16/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

An experimental compound from a family better known for harming brain cells, yet this member appears to support and regrow dopamine-making neurons, aid learning, and calm brain inflammation in animal studies. No human studies exist. It reliably damages DNA under sunlight and interacts dangerously with certain foods, medicines, and supplements. (Full Review)

Protocol

Dose
15–30 mg/day
Start low, titrate upward over roughly two weeks
Administration
Oral, once daily
Morning dosing preferred due to stimulatory effect
Cycling
4 weeks on / ≥4 weeks off
Limits cumulative genotoxic exposure and dopamine dysregulation
Time to effect
Cognitive & structural
~10 days
Neurotrophic and structural changes in animals
Stimulant & mood
A few days
Users report stimulatory and mood effects

Benefits

Contraindications
  • Other MAO inhibitors (phenelzine, tranylcypromine, selegiline)
  • Serotonergic prescription drugs (SSRIs, SNRIs, tramadol, triptans)
  • Pregnancy, breastfeeding, or those who could become pregnant
  • Bipolar disorder or psychosis
  • Photosensitivity disorders or history of skin cancer/melanoma
  • Uncontrolled hypertension or significant cardiovascular disease
  • Liver impairment (Child-Pugh Class B or C)
  • Minors
Key Interactions
  • Sympathomimetics and stimulants (amphetamines, pseudoephedrine, phenylephrine)
  • Serotonergic OTC agents (dextromethorphan, St. John's Wort)
  • Dopamine/serotonin precursors (L-DOPA, L-Tyrosine, 5-HTP) and other β-carbolines (harmine, harmaline)
  • Additive dopaminergic supplements (Bromantane)
  • Tyramine-rich foods (aged cheese, cured/fermented meats, soy sauce, sauerkraut)

Risk & Side Effects

  • Low: Photosensitivity and UV-induced DNA damage; monoamine oxidase inhibition effects; common physical side effects
  • Speculative: Genotoxicity and DNA intercalation; dopaminergic neurotoxicity at high doses; anhedonia and dopamine dysregulation; unknown long-term and reproductive safety

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg MAO-A inhibition raises hypertensive-reaction risk, especially with tyramine
Resting heart rate 55–70 bpm Detects sympathetic overstimulation from raised monoamines
ALT / AST ALT 10–26 U/L; AST 10–26 U/L Screens for hepatic strain from an unstudied compound metabolized by the liver
Homocysteine 5–7 µmol/L Marker of methylation balance, relevant for a methylated compound affecting one-carbon pathways

Cadence: Baseline, then at ~4 weeks, then every 3–6 months during continued cyclical use

Qualitative Assessment

  • Focus, mental clarity, and processing speed
  • Motivation and drive
  • Mood and, conversely, any blunting of pleasure (anhedonia)
  • Sleep quality and time to fall asleep
  • Headache, nausea, or stomach discomfort
  • Any skin changes or heightened sunburn sensitivity